XML 36 R26.htm IDEA: XBRL DOCUMENT v3.26.1
Business Segment: (Tables)
3 Months Ended
Mar. 31, 2026
Business Segment:  
Schedule of disaggregated amounts that comprise research and development expenses

For the Three Months Ended March 31, 

  ​ ​ ​

2026

  ​ ​ ​

2025

  ​ ​ ​

External clinical development expenses

$

10,352

$

26,191

Personnel related and stock-based compensation

 

2,512

 

12,825

Other research and development expenses

 

15,736

 

21,800

Total research and development expenses

$

28,600

$

60,816